Meaning and definition:IBRI ib'-ri (ibhri,'a Hebrew'): Ibrí is the capital of the northern region of Al Dhahirah. Ibri: perhaps descendant of Eber, also another name for an Israelite.
"We' re getting research to the sickbed quicker than ever." - Rainer Fischer
IBRI brings together for the first case bioscience and research university organizations to innovate and conduct more effective research in the United States and around the globe to enhance people' s quality of living. We will continue to grow depending on philanthropical assistance to finance research that will have a short-term impact on patients' survival.
Dr. Rainer Fischer came to IBRI in April 2017 as Chief Scientific and Innovation Officer. He was also head of the Department of Molecular Biotechnology at RWTH Aachen University, where he was appointed a special professorship in 2015. In addition, Fischer has a second professorship at the University of Maastricht, Netherlands, where he co-founded the Aachen-Maastricht Institute for Bio-based Materials (AMIBM) in 2015.
Mr Andersen, CFA and CFO, most recently worked as Vice President Finance and Corporate Controller for a bio-medical firm in Georgia. Prior to that, Andersen had several senior finance positions at Eli Lilly and Co., among others as director of investments for the company's retirement plans, where he was responsible for managing broadly diverse asset management mandates with total net worth of approximately $13 billion.
In addition, he was Finance Director for Mergers & Acquisitions, where he made mergers of national and multinational companies and provided invaluable guidance and negotiating assistance for IPOs. In his role as Finance Director and Controllers for Lilly USA, Andersen headed the finance and analytics teams of Lilly's US subsidiary, with over $10 billion in revenues, and acted as Finance Controllers, overseeing the company's accounts and in-house control.
Mr. Andersen holds a Bachelor of Science of Science and a Master of Science of Science degrees in Finance from Southern Utah University with honors and honors. Mr. Ross holds an MBA from the University of Michigan Ross School of Business. Mr Mark E. Craft kam im April 2018 als Executive Direktor of Commitment, Communication and Outside Affairs at IBRI.
Before he joined IBRI and since January 2014 he was Associate VP at Purdue University in West Lafayette, Ind. Before Purdue, he had senior management roles with growing responsibility in the areas of enterprise communication, sales and PR for Indiana-based businesses or departments of large groups such as Raytheon, Anthem, Duke Energy, Hillenbrand and Simon Property Group.
Mr. Bennett holds a Bachelor of Science in Communication from Southern Illinois University in Carbondale, Illinois, and a Ph. Before joining IBRI, she was Deputy Assistant Chancelor for Medical Progress and Deputy dean of the University of Illinois at Chicago (UIC) University of Medicine, where she led all funding efforts at the Colleges of Medicine to maximise personal and professional development work.
Before joining UIC, she held the roles of VP for Medical Developpment at KU Endeowment and supported the University of Kansas Medical Center, associated VP of the University of South Florida/USF Health and in senior management roles at Arizona State University and Wichita State University. Stephenie is a serviceman of digit significant outfit operation: the $1 large integer operation Illinois Initiatives, the operation for advantage at Arizona State University, and the $1. 2 large integer, far up:
While at KU Endowment, she was a member of the KU Institute for Advanced Medical Innovation research group, a pioneering role-playing role-playing role for the philanthropic, industrial and scientific communities in promoting innovation in the humanities. Ms. B.A. in Communication from Fort Hays State Univeristy in Hays, Kan.
She has also been to Arizona State University in Tempe, Arizona. and holds and absolviert ihren Executive Masters in Health Administration an der University of Illinois in Chicago. Mr Jay McGill, PhD is Chief Operating Officer (COO) des Indiana Bioscience Research Institute. Dr. McGill provides a solid grounding in industry, operation and innovations across industrial-academic borders.
Previously, Dr. McGill was Lilly Research Laboratories Lilly's Executive Vice President of Scientific and Technological alliances. As such, Dr. McGill acted as an intermediary between academia and Lilly Research Labs and managed Lilly's research-driven public-private partnership and alliances.
From 2012-2014, Dr. McGill worked as a temporary employee at BioCrossroads, where he was the Translational Scientific Officer. At BioCrossroads he supported several Indiana Clinical and Translational Institute (Indiana CTSI) at the Indiana University School of Medicine. Dr. McGill was also a key player in building the Indiana CTSI-Covance Clinic Phase 1 Clinic at IU Hospital and a key player in the establishment of the Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC).
Dr McGill, chef des opérations de guerre et Schatzmeister des Fairbanks Institute for Healthy Communities. Prior to BioCrossroads, Dr. McGill was Senior Director of Research Business Operations, where his roles include overseeing and managing all research-based (pre-clinical) collaborative ventures, collaborative ventures and contract manufacturing partnerships, as well as in vitro and in vivo biological, pre-clinical ODME and toxicological activities.
Dr. McGill was also in charge of the company's global QA and regulatory affairs. He was Interim COO of the Lilly China Research Developement Center (LCRDC) in Shanghai, China from December 2010 to June 2012. Following Eli Lilly's intention to set up a research and develop site in China, Dr. McGill headed a research and develop teams to help in identifying a site, build the plant and build the operation for LCRDC, which opened in June 2012.
Dr. McGill graduated with a Bachelor of Science of Science from the University of Georgia in Chemical Engineering and a Doctorate in Organics from Indiana University before joining Eli Lilly and Company in 1990 as a Senior Scientist in the Chemical Process Development Group. During 1998, he became a member of Discovery Chemicals Research and Technologies and served in various roles, among others as Head of Custom Synthesis Lab, Director of Discovery Chemicals Synthesis Group, Sr.
Manager - Global Chemical Industry Certification. As part of the reorganisation within Lilly Research Laboratories, all research-based research groups (chemistry, in vitro and in vivo biologicals, toxicology as well as ADME) were combined in 2008 under the direction of Dr. McGill as Senior Director External Research Operations. Dr. McGill has more than 25 years of expertise in pharmaceuticals research and develeopment, research collaboration and contract outplacement.
Dr. McGill is known for his leading role in developing novel and transformative partnering schemes. Dr. Mastracci is a molekular and evolutionary scientist from Indiana University School of Medicine at IBRI, where she was Assistant Research Professor in the Department of Pediatrics, the Herman B Wells Center for Pediatric Research and the Center for Diabetes and Metabolic Diseases.
Mr. Mastracci graduated with a bachelor's from the University of Guelph and a doctorate from the University of Toronto at the Lunenfeld-Tanenbaum Research Institute. Mr. Mastracci went to Columbia University and the Naomi Berrie Center for Diabetes Research in New York. In 2010, she received a renowned postdoc scholarship from the Juvenile Diabetes Research Foundation, which continues to promote her professional advancement and research.
These scholarships were collectively crucial to Mastracci's diabetic research and as a consequence she was enrolled at Indiana University School of Medicine, where she further expanded her research. Mastracci is currently focusing on how directed gene expression drives the evolution and differential production of endocrine disruptors in the human islets.
Part of the funding for this research is provided by a renowned Career Developement Award of the Juvenile diabetes Research Foundation. Mastracci is an assistant professor at the Department of Biochemistry and Molecular Biology at Indiana University School of Medicine. To study the signs that enable the pancreatic gland to develop and the recovery of betacells with the aim of developing new therapies for the onset of oncology.
Dr. Michael Pugia is a Research Fellow and Executive Vice President of the SCC. For 15 years he was Research and Developpment Manager, where he worked with industry leaders and businesses to develop next-generation analysis and diagnostics solutions. Pugia's main research interest is the advancement of individual bioanalytics for the detection of proteome markers in the areas of endo-crinology and cancer.
He was named Samuel Natelson Senior Investigator by the American Association of Chemistry recognizing his exceptional contributions to the promotion of chemical clinics and as the recipient of the first AI Free Memorial Lectureship. With 367 U.S. and international patent applications and 72 patent applications, Pugia has 55 scripts, 13 books and hundred of contributions to conferences and presentations on his name in a broad range of chemical fields.
PhD in chemical engineering from Texas Tech University and bachelor's in chemical engineering from Clarkson University. During his time in academia, Pugia was a visiting scholar at the University of Notre Dame and a clinical research professor at the University of Louisville Medical School.
Focus on transgenomics, protectedomics, metabolomics and lipidomic platforms to enable individual cellular immune assays as well as biomolecular asays. Dr. Robertson initially entered IBRI in mid-2015 as part of a on loan senior management programme at Eli Lilly and Company, but in mid-2017 he took up a full-time post at IBRI as he had the ability to promote cutting-edge research between various large and small and medium-sized biotech firms, academia and technological firms to promote problem-solving.
Most recently, he served as Senior Director of Research IT at Eli Lilly and Company, where he headed the IT staff to assist with Discovery deployments and operations at six research locations worldwide and nine functional/therapeutic areas. While leading IT at Lilly, Dr. Robertson structured Research IT to become a streamlined, more effective organisation, implemented the Research IT policy to leverage discoverability capabilities, provided new technologies and analytics through IT, improved HPC, clouds and large scale in-house information retention and analytics.
During his 10 years in management positions at Lilly, Dr. Robertson evolved several people within his organisation to move up to senior positions in other organisations within Lilly. After joining Lilly as a research assistant at Lilly Research Laboratories, he held a number of independant contributions and academic management positions before joining the IT organisation in 2010.
Dr. Robertson holds a Ph. D. in Chemical Physics from Florida State University and a Bachelor of Science of Science in Chemical Sciences with a Summa Cum Laude from Florida Southern College. Dr. Robertson was NRC/NRL Postdoctoral Research Associate at the Naval Research Laboratory in Washington, D.C., and then occupied various posts at Indiana University-Purdue University Indianapolis (IUPUI) from 1993 to 2000.
Most recently, he was Associate Scientist and Director of Technical and Administrative Services and Manager of the Facility for Computational Molecular Science at IUPUI before he joined Eli Lilly and Company in 2000. Award-winning author Eli Lilly and Company and IUPUI, he is a member of the American Chemical Society, the American Physical Society, as well as the fields of physic and math.
Focussing on the design of software and application that allow in-depth computer literacy to support scientists, clinical practitioners and the patient. Dr. Yusibov is a scientifically oriented leader with more than 15 years of operative and strategical management expertise in the field of bio-pharmaceutical R&D and commercial growth, with a particular emphasis on therapeutic products and immunotherapeutics.
His responsibilities at IBRI will, among other things, expand and strengthen IBRI's key competencies in pharmaceutical biotechnology through the establishment and management of a cross-functional array organisation, the development of translation-related research programmes and the establishment of alliances. Before coming to IBRI, he was Scientific Director and then General Manager of the Fraunhofer USA Center for Molecular Biotechnology, where he worked on strategy development and managed the development of a one-of-a-kind translation research organisation that received more than $150 million from government and non-governmental organizations.
In addition, Dr. Yusibov worked closely with regional and national lawmakers, business promotion bodies and public bodies to better adapt the Centre's activities to meet regulative directives and the needs of the markets. Yusibov was Assistant Professor at Thomas Jefferson University in Philadelphia after having held research posts at Purdue University in Lafayette, Indiana.
Its research focuses on the developpement and use of new technology for the vaccines and therapeutic agents. PhD in molecular biology from the Academy of Sciences in Moscow, Russia and M.S. in plant biochemistry and B.A. in biology from the University of St. Petersburg, Russia.